Saving Lives Is Expensive
Thursday, May 13th, 2010Popular Mechanics has an article about the shortage of snake and insect antivenin in the US.
Unfortunately, after Oct. 31 of this year, there may be no commercially available antivenom (antivenin) left. That’s the expiration date on existing vials of Micrurus fulvius, the only antivenom approved by the Food and Drug Administration for coral snake bites. Produced by Wyeth, now owned by Pfizer, the antivenom was approved for sale in 1967, in a time of less stringent regulation.
Wyeth kept up production of coral snake antivenom for almost 40 years. But given the rarity of coral snake bites, it was hardly a profit center, and the company shut down the factory that made the antivenom in 2003. Wyeth worked with the FDA to produce a five-year supply of the medicine to provide a stopgap while other options were pursued. After that period, the FDA extended the expiration date on existing stock from 2008 to 2009, and then again from 2009 to 2010. But as of press time, no new manufacturer has stepped forward.
This is how our system ‘works’. Drugs that are unnecessary or have deadly side effects can easily get approved, as long as the drug companies think there is a big enough market for them to justify paying for ‘approval’. That’s how you end up with anti-depressants that cause suicides and sleeping pills that cause unconscious people to drive their cars.
On the other hand, drugs that are absolutely necessary but have a niche market are dropped because pharmaceutical companies simply won’t bother spending the millions to billions of $ on testing and regulator ‘lobbying’ necessary to get it approved. It’s not that FDA testing is strict, effective or uncorruptible; it’s just expensive.
If we could only find a way to make getting bitten by deadly snakes and insects cool, we could create the demand needed to justify saving people’s lives.
